BSH 2022 | Antibody-drug conjugates in multiple myeloma
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses antibody-drug conjugates (ADCs) and their importance in the treatment of multiple myeloma. Dr Popat first highlights some of the novel therapies that have greatly impacted myeloma treatment, including proteasome inhibitors (PIs), immunomodulatory imide drugs (IMiDs), and monoclonal antibodies. Dr Popat then explains the emergence of ADCs, drawing focus on belantamab mafodotin, which has been approved and has shown promising results in the Phase II DREAMM-2 trial (NCT03525678). Following this, Dr Popat highlights some of the results from this study, including overall response rate (ORR) and the management of adverse events (AEs). To conclude, Dr Popat discusses the potential combination of belantamab mafodotin with other standard of care agents, such as bortezomib and lenalidomide. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
